Certa Therapeutics’ lead candidate, FT011, has hit the mark in a Phase II scleroderma trial, sparking Phase III plans as the firm edges closer to validating its approach of targeting an undrugged receptor in the inflammatory pathway.
FT011 is a first-in-class oral candidate that inhibits a previously undrugged G protein-coupled receptor (GPCR). The Phase II trial assigned...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)